Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01026779 · ClinicalTrials.gov registry record
Rotavirus Gastroenteritis and Vaccine Usage in Rhode Island
A clinical trial of Rotavirus Gastroenteritis, sponsored by Lifespan.
- Completed
- Registry status
- 803
- Enrollment target
- 1
- Study location
NCT01026779: Completed study of Rotavirus Gastroenteritis, sponsored by Lifespan.
NCT01026779 is a study of Rotavirus Gastroenteritis that has completed, run by Lifespan. The registered enrollment target is 803 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01026779, a study of Rotavirus Gastroenteritis, has completed, sponsored by Lifespan.
- COMPLETED
- Registry status
- 803 participants
- Enrollment target
- 1
- Study location
Study Summary
The goals of this study are to see what effects the introduction of RV5(RotaTeq) vaccine has had in the community both on the number of rotavirus-associated hospitalizations and on the strains of rotavirus circulating in the community. The investigators will use cases of rotavirus gastroenteritis identified on the wards at Hasbro Children's Hospital during the 2007-2009 rotavirus seasons for a case-control study to estimate rotavirus vaccine effectiveness in preventing rotavirus-associated hospitalizations. The investigators plan to assess rotavirus vaccine coverage in Rhode Island using the state vaccine registry and to examine whether and to what extent rotavirus vaccine was used outside the recommended age limits (off label) during the first 2 years of its implementation in Rhode Island. Finally using the state child health database, KIDSNET the investigators plan to investigate the reasons that children may not have received rotavirus vaccine in order to better target educational efforts for parents and health care providers.
Primary Outcome
Rotavirus vaccine effectiveness in preventing rotavirus-associated hospitalizations under field conditions
Conditions Studied
Study Locations (1)
Rhode Island
- Hasbro Children's Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 803 participants |
| Start Date | 2009-07 |
| Est. Completion | 2019-11-01 |
What the finished NCT01026779 record still lists
NCT01026779 is an observational study that tracks outcomes without assigning an intervention. The registered 803 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Rotavirus Gastroenteritis appearing as the primary indexed condition, and to 0 interventions.
NCT01026779 reports a single indexed study location in Rhode Island.
Frequently Asked Questions
What is clinical trial NCT01026779 about?
NCT01026779 is a clinical study titled "Rotavirus Gastroenteritis and Vaccine Usage in Rhode Island". The goals of this study are to see what effects the introduction of RV5(RotaTeq) vaccine has had in the community both on the number of rotavirus-associated hospitalizations and on the strains of rotavirus circulating in the community. The investigators will use cases of rotavirus gastroenteritis id...
What is the current status of trial NCT01026779?
This trial is currently completed. The enrollment target is 803 participants. The study started on 2009-07. Estimated completion is 2019-11-01.
What conditions does trial NCT01026779 study?
This clinical trial studies the following conditions: Rotavirus Gastroenteritis.
Who is sponsoring clinical trial NCT01026779?
This trial is sponsored by Lifespan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01026779 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04423211 · 804 participants · Phase 3
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- NCT06522022 · 804 participants · NA
PTSD Screening in Pregnant Black Women
- NCT03524430 · 801 participants · NA
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
- NCT04613596 · 806 participants · Phase 2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia